Journal Watch · Frontiers in Immunology · 2026

Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.

This review summarizes current advances in NS1-based dengue vaccine development and progress in the <i>Bacillus subtilis</i> spore-based immunization strategy against severe dengue.

Zulkifli N, Shin OS, AbuBakar SFrontiers in Immunology3 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1809605PMID: 42523811Study type: review / perspective

TL;DR

This review summarizes current advances in NS1-based dengue vaccine development and progress in the <i>Bacillus subtilis</i> spore-based immunization strategy against severe dengue.

Key findings

  • In this context, immunization against NS1 offers a strategic advantage by eliciting immune responses that may contribute to early control of virus replication while simultaneously mitigating NS1-mediated vascular pathology.
  • A vaccine delivery platform that would stimulate protective immune responses yet avoid the potential pathologic effects of NS1, hence, is needed. <i>Bacillus subtilis</i> spores antigen delivery platform stands out as a promising platform for its safety, stability, and inherent adjuvant properties.
  • This review summarizes current advances in NS1-based dengue vaccine development and progress in the <i>Bacillus subtilis</i> spore-based immunization strategy against severe dengue.

What they did

More recently, increasing evidence has highlighted the importance of T cell-mediated immunity and anti-non-structural protein 1 (NS1)-specific responses in suppressing DENV replication and reducing disease severity. DENV NS1, however, is known to be associated with severe dengue pathologies.

Full abstract (original)

Background: Severe dengue is characterized by marked vascular leakage, hemorrhagic manifestations, and organ impairment, largely driven by immunopathological mechanisms. Traditional vaccine approaches focusing on inducing neutralizing antibodies against DENV structural antigens have shown limitations and, under certain conditions, may also worsen infection through antibody-dependent enhancement (ADE) of infection.

What they did: More recently, increasing evidence has highlighted the importance of T cell-mediated immunity and anti-non-structural protein 1 (NS1)-specific responses in suppressing DENV replication and reducing disease severity. DENV NS1, however, is known to be associated with severe dengue pathologies.

Results & conclusions: In this context, immunization against NS1 offers a strategic advantage by eliciting immune responses that may contribute to early control of virus replication while simultaneously mitigating NS1-mediated vascular pathology. A vaccine delivery platform that would stimulate protective immune responses yet avoid the potential pathologic effects of NS1, hence, is needed. <i>Bacillus subtilis</i> spores antigen delivery platform stands out as a promising platform for its safety, stability, and inherent adjuvant properties. This review summarizes current advances in NS1-based dengue vaccine development and progress in the <i>Bacillus subtilis</i> spore-based immunization strategy against severe dengue.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1809605 · PubMed 42523811.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

This review summarizes current advances in NS1-based dengue vaccine development and progress in the <i>Bacillus subtilis</i> spore-based immunization strategy against severe dengue.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. More recently, increasing evidence has highlighted the importance of T cell-mediated immunity and anti-non-structural protein 1 (NS1)-specific responses in suppressing DENV replication and reducing disease severity.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1809605. PubMed ID: 42523811. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zulkifli N, Shin OS, AbuBakar S. Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1809605.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-dengue-through-mucosal-vaccination-the-potential-of-ns1-and-ba-809605/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides